期刊
JOURNAL OF CLINICAL MICROBIOLOGY
卷 50, 期 11, 页码 3747-3750出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/JCM.02037-12
关键词
-
类别
资金
- Pfizer [WS963566]
We evaluated the Vitek2, Etest, and MIC Test Strip (MTS) methods of tigecycline susceptibility testing with 241 expanded-spectrum cephalosporin-resistant and/or carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii clinical isolates by using dry-form broth microdilution (BMD) as the reference method. The MIC(50/90)s were as follows: BMD, 1/4 mu g/ml; Vitek2, 4/>= 8 mu g/ml; Etest, 2/4 mu g/ml; MTS, 0.5/2 mu g/ml. Vitek2 produced 9.1/21.2% major errors, Etest produced 0.4/0.8% major errors, and MTS produced no major errors but 0.4/3.3% very major errors (FDA/EUCAST breakpoints). Vitek2 tigecycline results require confirmation by BMD or Etest for multidrug-resistant pathogens.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据